Capricor Therapeutics shares plunged 58.3% in pre-open trading after the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 on July 29 that the Phase 3 HOPE-3 trial failed to demonstrate substantial evidence of deramiocel’s effectiveness for cardiomyopathy in Duchenne muscular dystrophy.
The advisory panel’s lopsided decision followed a contentious session in which company representatives and FDA staff disagreed over which statistical analysis plan should govern the trial’s efficacy results. Capricor’s CEO, Linda Marbán, told committee members that the FDA’s briefing materials relied on an unsigned, incomplete internal draft plan rather than the finalized analysis plan that Capricor used to run the study.
Investors reacted immediately. The negative panel outcome prompted a fresh round of analyst downgrades that accelerated selling pressure. Piper Sandler cut its rating from Overweight to Neutral and lowered its price target from $58 to $2, positioning for an outright FDA rejection. H.C. Wainwright reduced its stance from Buy to Neutral and removed its price target entirely, assigning no value to deramiocel - the asset that had supported the firm’s clinical valuation model for Capricor. These actions came on top of earlier downgrades issued in the days before the advisory vote by B. Riley, Roth Capital, and Alliance Global Partners, which had already driven the stock sharply lower.
Insider transactions add another negative signal. Company insiders sold roughly $3.1 million of Capricor stock over the past three months, with no reported insider buying during that period.
The market environment offered no clear explanation for the stock’s collapse. Major indexes were firmer on the day - the NASDAQ was up 1.3%, the S&P 500 gained 0.6%, and the Dow Jones advanced 0.4% - indicating that the selloff in Capricor was driven by company-specific regulatory risk rather than broad market weakness.
Deramiocel represents the company’s second Biologics License Application attempt. Capricor’s original BLA was rejected in July 2025 for lack of substantial evidence of effectiveness. With the advisory committee’s negative recommendation, a second Complete Response Letter now appears to be the most likely regulatory outcome ahead of the August 22 PDUFA date.
The combination of a near-unanimous negative advisory panel vote, a wave of analyst downgrades that stripped nearly all expected value from the lead asset, and the looming possibility of a second FDA rejection has created severe downside pressure for the stock. Capricor shares were trading at $2.742 after the move, a steep decline from the company’s 52-week high of $40.37.
With the market increasingly pricing in a scenario where deramiocel will not be approved, Capricor’s potential future value now rests largely on its earlier-stage exosome pipeline. Those programs remain in development, but the advisory vote and analyst responses have moved the company’s near-term valuation drivers away from the lead asset that had anchored investor expectations.
Clear summary
The FDA advisory committee voted 9-3 against deramiocel, concluding the Phase 3 HOPE-3 trial did not provide substantial evidence of effectiveness. A dispute over which statistical analysis plan governed the trial’s efficacy results was central to the meeting. The negative committee recommendation triggered aggressive analyst downgrades and drove the stock sharply lower, with the market now anticipating a likely second rejection before the August 22 PDUFA date.
Key points
- The advisory committee voted 9-3 against deramiocel’s effectiveness for treating cardiomyopathy in Duchenne muscular dystrophy.
- Piper Sandler cut its rating from Overweight to Neutral and cut its price target from $58 to $2; H.C. Wainwright moved from Buy to Neutral and removed its price target entirely.
- Capricor share price dropped to $2.742 from a 52-week high of $40.37 as the market priced in the likelihood of another FDA rejection; broader indices were positive on the day, signaling company-specific regulatory risk.
Risks and uncertainties
- Regulatory risk - A second Complete Response Letter appears likely ahead of the August 22 PDUFA date if FDA follows the advisory committee recommendation.
- Valuation risk - Analysts have removed most or all value assigned to deramiocel, shifting future value dependence to earlier-stage exosome programs whose outcomes and timelines are uncertain.
- Investor sentiment risk - Recent insider selling of approximately $3.1 million over the past three months, without reported insider buying, may weigh on investor confidence.